comprehensive -WSS

comprehensive

author：focus 2025-10-01 20:12:18 - browse：7

An advisory committee to the Food and Drug Administration will convene on Tuesday to evaluate the benefits of renal denervation, a one-time surgical procedure that works to reduce blood pressure. The promise — and the potential market — is enormous, but the data on how well the procedure works remains contentious.

The committee will evaluate data from two companies vying for market approval: ReCor Medical, a startup owned by Japanese company Otsuka Medical Devices, and device giant Medtronic, both of which have made surgical systems to treat hypertension.

Data from an analysis of three randomized clinical trials of ReCor Medical’s device showed a modest decrease in blood pressure after two months compared to a control group that received a placebo procedure. Medtronic’s late-stage trial showed that renal denervation reduced hypertension when measuring blood pressure in the doctor’s office, but did not show a reduction in blood pressure when patients measured it at home over 24 hours. At-home blood pressure is considered the more accurate measure, as blood pressure levels tend to artificially rise with anxiety in the clinic. Neither study presented serious safety concerns.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Ionis has late

leisure time

hotspot

WSS

Stem cell biologist probes earliest stages of human development

How the Dana

Health tech startups drop sharply from 2021 highs

Medicare drug price negotiation continues, as pharma counteroffers

He's 19 months old and has one of the world’s rarest diseases

Immune cells and nerve overgrowth may explain recurring UTI pain

explore

comprehensive

explore

The high cost of giving birth even with insurance

Inequities make cancer less preventable for women: report

State Dept. review finds Biden bears some blame for Afghanistan failures

How the Dana

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Ozempic has benefits for kidney disease as well as diabetes

The cancer drug shortage isn’t new — and neither are the solutions

How the Dana

Medicare proposal to cover medical devices draws a mixed reaction

Senator probes 340B programs at Cleveland Clinic, Bon Secours

knowledge

Biden's 'march

Immune cells and nerve overgrowth may explain recurring UTI pain

A new approach to psychiatric drug development

FDA seeks to regulate lab

Mindstrong's demise and the future of mental health care

Paxlovid should be available without a positive Covid test

leisure time

hotspot

hotspot

explore